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Abstract
A small subpopulation of highly adaptable breast cancer cells within a vastly heterogeneous population drives cancer
metastasis. Here we describe a function-based strategy for selecting rare cancer cells that are highly adaptable and drive
malignancy. Although cancer cells are dependent on certain nutrients, e.g., glucose and glutamine, we hypothesized that
the adaptable cancer cells that drive malignancy must possess an adaptable metabolic state and that such cells could be
identified using a robust selection strategy. As expected, more than 99.99% of cells died upon glutamine withdrawal from
the aggressive breast cancer cell line SUM149. The rare cells that survived and proliferated without glutamine were highly
adaptable, as judged by additional robust adaptability assays involving prolonged cell culture without glucose or serum. We
were successful in isolating rare metabolically plastic glutamine-independent (Gln-ind) variants from several aggressive
breast cancer cell lines that we tested. The Gln-ind cells overexpressed cyclooxygenase-2, an indicator of tumor
aggressiveness, and they were able to adjust their glutaminase level to suit glutamine availability. The Gln-ind cells were
anchorage-independent, resistant to chemotherapeutic drugs doxorubicin and paclitaxel, and resistant to a high
concentration of a COX-2 inhibitor celecoxib. The number of cells being able to adapt to non-availability of glutamine
increased upon prior selection of cells for resistance to chemotherapy drugs or resistance to celecoxib, further supporting a
linkage between cellular adaptability and therapeutic resistance. Gln-ind cells showed indications of oxidative stress, and
they produced cadherin11 and vimentin, indicators of mesenchymal phenotype. Gln-ind cells were more tumorigenic and
more metastatic in nude mice than the parental cell line as judged by incidence and time of occurrence. As we decreased
the number of cancer cells in xenografts, lung metastasis and then primary tumor growth was impaired in mice injected
with parental cell line, but not in mice injected with Gln-ind cells.
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Introduction
The success of cancer depends on ongoing generation of genetic
and epigenetic heterogeneity in cancer cells, combined with the
selection of cells that are capable of adapting and surviving
numerous obstacles in the body [1–6]. The process of metastasis,
requiring multiple rate-limiting steps, is very inefficient. Less than
0.01% of cancer cells within the blood circulation survive to
produce experimental lung metastasis [5–7]. Cancer cells present
in metastases are also heterogeneous, only a small subpopulation
of them being able to produce new metastasis in patients or in
experimental models [5]. Tumor heterogeneity can be explained
by 1) developmental hierarchy wherein a small percentage of cells
are stem cell-like thus giving rise to progeny of different
characteristics than the mother cell [6], and/or 2) high genomic
instability of metastatic cancer cells [8,9]. In breast cancer, indeed
in most cancers, clinical metastasis is an end result of a long
Darwinian evolution-like selection process spanning decades, in
which the most adaptable cancer cells persist. The selection
pressures in the body include metabolic challenges, and attacks
from the immune system. To develop effective therapeutic
strategies against metastatic disease, it would be desirable to use
in vitro systems that contain cellular heterogeneity and high
adaptability similar to what is present in clinical metastases.
In vitro selection approaches are ideally suited for selecting cell
variants that can survive metabolic challenges. Numerous studies
deal with investigating how oncogenes cause dysregulation of
metabolism, particularly aerobic glycolysis, which increases
glucose utilization in cancer cells [10]. Our approach is different
in that we decided to utilize the adaptability of metabolic state for
selecting metastatic cancer cells from a heterogeneous population.
One important reason behind our approach is that disseminated
tumor cells present in the bone marrow of stage I–III breast cancer
patients survive for years in a relatively dormant state before
causing clinical metastasis [11,12]. So the cancer cells that are
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survive metabolic challenges imposed for prolonged periods.
Glutamine (Gln) has important roles in cancer cells in addition
to being a building block in proteins, including being a source of
carbon and nitrogen for anabolic pathways [13]. Glutamine is also
essential for the uptake of essential amino acids, which involves
simultaneous efflux of Gln using a bidirectional transporter [14].
In this study, we investigated whether there are variant cells
present in aggressive breast cancer cell lines that can survive lack
of Gln, and whether such cells are adaptable and therefore more
tumorigenic and metastatic than the parental cell line. Depen-
dence of cancer cells on exogenous Gln is driven by Myc protein,
which suppresses miR-23a and miR-23b, leading to the induction
of glutaminase (GLS) [15]. Myc protein, which is frequently
overexpressed in aggressive breast cancers, is a key regulator of
metabolism [16] and it is also well known for driving poor-
prognosis gene expression signatures and an embryo-like pheno-
type [17,18].
COX-2 plays a key role in breast cancer metastasis as revealed
by studies with COX-2 overexpressing breast cancer cell lines, a
xenograft mouse model of bone metastasis, and the use of a COX-
2 inhibitor in a bone metastasis model [19]. The molecules whose
expression correlates with COX-2 overexpression in metastatic
clones include well known NFkB targets urokinase plasminogen
activator and interleukin-8 that are involved in invasion and
angiogenesis [20,21]. Others have provided convincing evidence
for the involvement of COX-2 in breast cancer metastasis to lung
and to brain [22,23]. Using a commonly used sphere culture
method developed in another laboratory, we found that COX-2
has an important role in cancer stem-like cells [24]. COX-2
overexpression promotes genomic instability and also leads to
therapeutic resistance [25,26]. Aggressive breast cancers, including
inflammatory breast cancers (IBC), overexpress a number of
NFkB target genes. In an analysis of 60 NFkB target genes, 35
were found to be overexpressed in primary tumors in IBC [27].
Interestingly, COX-2 and CXCL1 were the only two genes of the
35 that are also co-expressed in metastases [27]. Importantly,
COX-2 expression in the primary tumor of stage I-III breast
cancer patients predicts tumor cells dissemination to bone marrow
[28], which is known to predict metastasis in the future [11].
Significantly, NFkB inhibition in SUM149 IBC cell line inhibits
metastasis in nude mice [29]. With this overwhelming evidence in
support of COX-2 involvement in breast cancer metastasis, we
chose to analyze COX-2 overexpression as an indicator of
metastatic potential of in vitro selected metabolically plastic cancer
cells, prior to xenograft experiment in nude mice. We also
investigated using siRNA-mediated knockdown how COX-2
signals differently in Gln-ind cells as compared to other COX-2
overexpressing cells.
Results
Selection of Gln-ind variants from aggressive Gln-
addicted breast cancer cell lines
We began by investigating the dependence of breast cancer cell
lines on Gln in culture medium. Our approach was to determine
the subpopulation of cells that would survive long-term. We
observed that Gln withdrawal did not appreciably inhibit the
growth of normal MCF10A, pre-malignant MCF10A-COX2, or
poorly metastatic MCF7 cell lines (Fig. 1). There was approxi-
mately 50% decrease in cell number in all 3 cases as compared to
control in 4 days, but then surviving cells grew to confluency and
could be cultured long term. In contrast, Gln withdrawal severely
inhibited the metastatic cell lines MDA-MB-231, SUM149, and
4T1 (.99% of cells died in all 3 cell lines). These results indicate
that breast cancer cell lines are addicted to Gln, and the degree of
addiction correlates with metastatic ability of cell lines. We
followed luciferase-transfected SUM149-Luc cells in culture
medium lacking Gln to determine whether some rare cells would
survive several weeks without Gln. More than 99.99% cells died
under these conditions. However, we were surprised to find that a
few cells not only survived but resumed proliferation in Gln-free
medium. We obtained 13 colonies of such cells that were easily
visible to the naked eye in four weeks in a representative dish that
originally contained a half million cells. Therefore, the proportion
of cells that survived and proliferated was 0.01% or less. We were
able to culture these Gln-independent (Gln-ind) variant cells in a
Gln-free medium for multiple passages (.16). We were able to
similarly select rare Gln-ind cells from most breast cancer cell
lines, including some very aggressive breast cancer cell lines in
addition to SUM149, although they differed in properties (Fig. 2,
Table 1). For example, rare Gln-ind colonies selected from the
following cell lines could be cultured long-term in glutamine-free
medium: SUM149-FP (cell line established in our laboratory from
a fat pad tumor), SUM190 IBC cell line, 4T07, and 168FARN
(both mouse breast cancer cell lines). On the other hand, although
some rare cells survived in MDA-MB-231 and MDA-MB-231-
BSC60 (metastatic clone) human and 4TI mouse breast cancer cell
lines, they required Gln for long-term proliferation. Significantly,
we were able to culture Gln-ind cells from freshly isolated fat pad
tumors from the nude mice that were inoculated with either
parental SUM149 cell line or its in vitro selected Gln-ind variants (B
Singh, S Madan, and A Lucci, unpublished observations), further
emphasizing the relevance of such cells in tumor formation.
Figure 1. Effect of glutamine deprivation on breast cancer cell
lines. Indicated cell lines were cultured with or without Gln as
described in Materials and Methods. Photographs of cultures in
complete medium (+Gln) versus in Gln-free medium (2Gln) are shown.
Results are summarized in Table 1.
doi:10.1371/journal.pone.0036510.g001
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To first address how Gln-ind cells survived lack of Gln, we
determined whether they had a reduced level of GLS (which
converts Gln to Glu) than the parental cell line. Our western blot
analysis showed that the Gln-ind variants had a GLS level less
than 20% that in parental SUM149 cells (Fig. 3). We interpret that
the absence of exogenous Gln makes it necessary that the
proliferating Gln-ind cells synthesize and preserve sufficient Gln
needed for essential functions (e.g., protein synthesis), and
therefore reduce their GLS level. In addition, metabolic enzymes
including GLS are well known for their allosteric regulation to suit
intracellular levels of substrates and products; such regulation is
also likely to occur under lack of exogenous Gln. Next, we
determined whether the key regulator of GLS, i.e., Myc protein,
was also down-regulated in Gln-ind cells. Significantly, we found
that the reduction in GLS level in Gln-ind cells was not
accompanied by a reduction in Myc level. On the contrary,
Gln-ind cells contained a modestly elevated level of Myc protein
(50% more than the parental cell line; Fig. 3).
We noted that b-actin level was lower in the Gln-ind cells than
in the parental cell line, both by western blotting and by
Coomassie blue staining (actin-sized band is indicated by an
arrow in Fig. 3). Therefore, we used additional controls (Hsp90
and GAPDH) for normalizing gel loading. Protein levels of
Figure 2. Selection of Gln-ind variants from breast cancer cell lines. (A–C) Half a million cells were plated in a 10-cm dish. The next day, the
medium was changed to a Gln-free medium containing dialyzed fetal bovine serum. Colonies of cells growing under these conditions for 2–4 weeks
were photographed. (D, E) Dishes of colonies stained with crystal violet. (F) SUM149-Luc-Gln-ind cells growing in Gln-free medium.
doi:10.1371/journal.pone.0036510.g002
Table 1. Glutamine-dependence of breast cancer cell lines.
Cell line Properties Growth inhibition in Gln-free medium
MCF10A Normal Weak inhibition, grew to confluency
MCF10A-COX2 Premalignant Weak inhibition, grew to confluency
MCF7 Poorly metastatic Weak inhibition, grew to confluency
MDA-MB-231 Metastatic Severe inhibition, but variants survived
BSC60 Highly metastatic, bone-seeking clone Severe inhibition, but variants survived
SUM149 Metastatic and locally aggressive Severe inhibition, but variants grew long term
SUM149-Luc Metastatic and locally aggressive Severe inhibition, but variants grew long term
SUM149-Luc-FP Cultured from a fat pad xenograft Severe inhibition, but variants grew long term
SUM190 Metastatic and locally aggressive Severe inhibition, but variants grew long term
4T1 Highly metastatic Severe inhibition, but variants yielded colonies
4T07 Forms micrometastases in lungs Severe inhibition, but variants grew long term
168FARN Yields lymph node metastases Severe inhibition, but variants grew long term
BSC60, metastatic clone derived from MDA-MB-231.
Luc, luciferase transfected cell line.
doi:10.1371/journal.pone.0036510.t001
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also lower in Gln-ind cells than the parental cell line, which could
be a part of the overall slow rate of glycolysis in the absence of
glutamine.
Overexpression of COX-2 in Gln-ind cells
To determine whether Gln-ind cells have a higher malignancy
potential than the parental cell line, we first analyzed COX-2
protein level. We found by western blotting that Gln-ind cells
produce approximately 5-fold higher level of COX-2 protein than
the parental cell line (Fig. 3). Next, we determined whether there is
a close linkage between increased COX-2 level and decreased
GLS level in Gln-ind cells. We found that siRNA-mediated
knockdown of COX-2 did not alter GLS level in Gln-ind cells
indicating that a high COX-2 expression is not directly linked with
a reduced GLS level (Fig. 4). This result prompted us to further
investigate the relationship of COX-2 signaling with the synthesis
of metabolic enzymes that are regulated by Myc protein, including
GLS, hexokinase II, and lactate dehydrogenase A (LDHA). We
knocked down COX-2 by siRNA both in Gln-ind cells that
overexpress COX-2 and in celecoxib-resistant SUM149-CER cells
that overexpress COX-2 [30], to determine whether COX-2
signals differently in metabolically plastic cells as compared to
other cells. On the basis of the number of cells that survive
selection without Gln (,0.01%) versus the cells that survive
celecoxib treatment (1–10%), Gln-ind cells may be a small
subpopulation of COX-2
high cells present in SUM149 cell line
that survive in the presence of celecoxib. COX-2 knockdown in
SUM149-CER cells, but not in Gln-ind cells, resulted in reduced
levels of Myc protein and the metabolic enzymes Myc regulates:
GLS, hexokinase II, and LDHA (compare Figs. 4 and 5). We
interpret that signaling nodes in Gln-ind cells, e.g., COX-2 and
Myc, communicate with metabolic state in a highly adaptive
manner (see model in Fig. 6). Gln-ind cells can lower the GLS level
in response to the non-availability of exogenous Gln even when
Myc and COX-2 levels are high.
We also analyzed the effect of COX-2 knockdown in SUM149-
CER cells on epidermal growth factor receptor (EGFR) level by
western blotting. EGFR plays a major role in aggressive breast
cancers, including IBC. EGFR overexpression is also important in
the survival of breast cancer cells under low-glucose culture
conditions, this effect being independent of its protein kinase
Figure 3. Low glutaminase level in Gln-ind cells. Selected
proteins likely to be involved in Gln addiction (GLS, Myc) and in
metastasis (COX-2, Myc) were analyzed by western blotting in Gln-ind
and parental SUM149-Luc cells. Since the b-actin level was found to be
lower in the Gln-ind cells than in the parental cell line by western
blotting, we included additional gel loading controls: western blotting
with Hsp90 and GAPDH antibodies, and Coomassie blue staining of a
gel run in parallel.
doi:10.1371/journal.pone.0036510.g003
Figure 4. COX-2 knockdown does not affect Myc, GLS, HK II,
and LDH A protein levels in Gln-ind cells. We transfected SUM149-
Gln-ind cells growing without Gln with a COX-2-specific siRNA or with a
control siRNA and analyzed the levels of Myc and some proteins
involved in Myc-mediated glycolysis (hexokinase II and lactate
dehydrogenase A) and glutaminolysis (glutaminase) by western
blotting compared with those in the parental SUM149-Luc cell line.
doi:10.1371/journal.pone.0036510.g004
Figure 5. COX-2 function is linked with Myc in regulating
glycolysis and glutaminolysis in the COX-2-overexpressing,
celecoxib-resistant SUM149-CER cell line. We transfected
SUM149-CER cells with a COX-2-specific siRNA or with a control siRNA
and analyzed the levels of Myc and some proteins involved in Myc-
mediated glycolysis (hexokinase II and lactate dehydrogenase A) and
glutaminolysis (glutaminase) by western blotting.
doi:10.1371/journal.pone.0036510.g005
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resulted in a significant reduction in EGFR level in SUM149-CER
cells (Fig. 5) suggesting a crosstalk between COX-2 signaling and
EGFR expression.
Mechanism of COX-2 overexpression
A common trigger for COX-2 overexpression is oxidative stress.
To determine whether oxidative stress may be driving COX-2
overexpression in Gln-ind cells, we analyzed the intracellular level
of reduced glutathione (GSH), an indicator of redox status. We
found that Gln-ind cells have a lower level of GSH than the
parental SUM149-Luc parental cell line, thus supporting our
hypothesis (Fig. S1). Because of an extremely low level of reduced
glutathione in Gln-ind cells, which is close to lower limit of
detection in our assay, we were not able to accurately determine
percentage of reduction. We also found that Gln-ind cells have a
low level of oxidized glutathione (GSSG) as well (approximately
40% of the level in parental cell line; Fig. S1), indicating that they
have a low capacity to regulate redox status. In an alternative
approach, we found that addition of N-acetyl cysteine (NAC) in
culture medium for 24 hours to lower oxidative stress resulted in a
lower COX-2 production in Gln-ind cells (Fig. 7). At 1 mM dose
NAC inhibited COX-2 production in Gln-ind cells, but not in
parental SUM149-Luc cells (Fig. 7). At a higher 2.5 mM dose
NAC inhibited COX-2 in both Gln-ind and parental cell line,
although percent inhibition was higher in Gln-ind cells. Stress
mediated induction of COX-2 may involve NFkB transcription
factor binding to COX-2 gene promoter, although other
mechanisms are also possible. To determine whether NFkBi s
involved, we added a specific inhibitor of NFkB activation
pathway, BAY-11-7082, to the culture medium for 24 hr. Analysis
of COX-2 by western blotting showed that BAY-11-7082
treatment caused a decrease in COX-2 level in Gln-ind cells
growing with or without Gln (Fig. S2). COX-2 level in the parental
cells remained unaffected under these conditions (Fig. S2).
Adaptability in Gln-ind cells
We found that Gln-ind cells can utilize Gln as efficiently as the
parental cell line. Within a day after adding Gln to the culture
medium, we observed an induction of GLS (Fig. 8 top). The Gln-
ind cells proliferated approximately 50% slower in the Gln-free
medium than the parental cell line proliferated in the Gln-
containing medium. However, upon the addition of Gln, Gln-ind
cells resumed a proliferation rate similar to that of the parental cell
line. These results indicate that the rare cells that survive the lack
of Gln are not defective in Gln utilization; instead, they possess a
more adaptable metabolic state. After culture in Gln-containing
medium for 8 passages, Gln-ind cells maintained the ability to
proliferate without Gln. Gln withdrawal slowed their growth, as
expected, but most cells survived and resumed proliferation (Fig. 8
bottom). These results indicate that Gln-ind cells maintain an
adaptable metabolic state in Gln-containing medium.
Next, we determined whether the SUM149-Gln-ind variants
are adaptable under other metabolic challenges, e.g., a non-
availability of glucose. We cultured cells in glucose-free medium
for 28 days (the medium included Gln for both cell lines) and then
replaced the medium with complete medium containing glucose.
To determine the number of (clonogenic) cells that survived the
lack of glucose, we stained the dishes with crystal violet after 13
days in complete medium. The Gln-ind variants survived lack of
glucose better than the parental cell line did, as judged by the
number of colonies (Fig. 9). One way to explain this result is that
non-availability of Gln forces a selection of cells that can slow their
overall metabolism, including glucose utilization. In support of this
Figure 6. Model summarizing western blot analysis and
additional data. Adaptable Gln-ind cells have high levels of COX-2
and Myc proteins, but they are able to dissociate Myc expression and
GLS expression. The majority of cells lacking such adaptability may have
perished in the initial selection in Gln-free medium. Broken arrows
indicate adaptability to dissociate COX-2 function from Myc function,
and Myc function from GLS level in Gln-ind cells, as identified in this
study.
doi:10.1371/journal.pone.0036510.g006
Figure 7. A reduction in COX-2 level upon treatment with N-acetyl cysteine. We exposed parental SUM149-Luc and Gln-ind cell lines, both
growing in a medium with glutamine, to N-acetyl cysteine for 24 hours before subjecting them to western blotting using equal volumes of cell
lysates. Since b-actin was not a reliable indicator of protein loading, we ran a gel in parallel and stained it with Coomassie blue. Lane numbers 1–6 at
the bottom in left panel correspond to lane numbers 1–6 in the right panel.
doi:10.1371/journal.pone.0036510.g007
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50% lower level of a glycolytic enzyme glyceraldehyde 3-
phosphate dehydrogenase as compared to the parental cell line
(Fig. 3). Since glucose has major roles in cellular metabolism, and
also in governing the metabolic state [32–34], the ability of Gln-
ind cells to survive without glucose implies that they are highly
adaptable.
Survival and growth of Gln-ind cells without serum
Over the course of the disease, metastatic cancer cells must be
able to survive not only metabolic challenges, but also a lack of
growth factors. Therefore, it may be useful to know whether Gln-
ind cells are more capable of surviving without growth factors than
the parental cell line. We have reported previously that COX-2
overexpression in MCF10A cell line can reduce the requirement of
EGF in the culture medium for cell growth [25]. We analyzed the
effect of withdrawing serum from the culture medium for an
extended period (25 days). We found that some Gln-ind cells
survived and proliferated, yielding large colonies, while the
parental cell line did not yield any such colonies (Fig. 10A). This
result suggests that the Gln-ind cells are less dependent on growth
factors for their survival and growth. This property could be
potentially advantageous in the process of tumor growth and
metastasis by reducing a dependence on stroma/microenvironment.
Gln-ind cells are anchorage-independent and resistant to
doxorubicin and paclitaxel
Next, we performed some in vitro assays to determine whether
the Gln-ind cells were more aggressive than the parental cell line.
First, in soft-agar assay to determine their anchorage-independent
growth, the Gln-ind cells yielded more and much larger colonies
than the parental cell line (Fig. 10B). Then we compared Gln-ind
and parental cells for their ability to survive in presence of
commonly used chemotherapeutic drugs doxorubicin and pacli-
taxel. The cells were exposed to 200 nM doxorubicin or 5 nM
paclitaxel for 7 days in a medium containing glutamine.
Approximately 99% cells died under this treatment. To determine
the relative survival of resistant cells, we removed the drug by
changing the culture medium with the fresh medium without drug,
and allowed time for colonies to grow before staining them. In this
manner we found that Gln-ind cells yielded more colonies than
parental cells under both doxorubicin and paclitaxel treatments
(Fig. 11). Thus, a selection for an adaptable metabolic state in
cancer cells also selects for chemotherapy resistance. As a
complimentary approach to show a relationship between Gln-
ind phenotype and chemotherapeutic resistance, we found that
Figure 8. Glutamine-independent phenotype is adaptable but
stable. Top panel: Induction of GLS upon growth in glutamine-
containing medium. SUM149-Gln-ind cells growing in Gln-free medium
were shifted to Gln-containing medium, and GLS was analyzed by
western blotting at different time points after the medium change.
Bottom panel: Morphologies of cells growing under different
conditions are shown. (A) Gln-ind cells growing without Gln. (B) Gln-
ind cells growing in the presence of Gln (they exhibited faster growth
and altered morphology upon growth with Gln). (C) Gln-ind cells were
maintained in Gln-containing medium for 8 passages and then
switched to Gln-free medium for 7 days.
doi:10.1371/journal.pone.0036510.g008
Figure 9. Higher adaptability/survival of Gln-ind versus
parental cells in the absence of glucose. Cell cultures were
deprived of glucose for 28 days and then allowed to recover and grow
for 13 days before crystal violet staining of colonies. Gln-ind cells (right)
yielded a large number of colonies, although the colonies were of
smaller size.
doi:10.1371/journal.pone.0036510.g009
Figure 10. (A) Higher adaptability/survival of Gln-ind versus parental
cells in the absence of serum. Cell cultures were deprived of serum for
25 days, and resulting colonies were stained with crystal violet. (B)
Higher anchorage-independence of Gln-ind versus parental cells.
Twelve thousand cells were cultured in Gln-containing medium with
0.35% low-melt agarose for 23 days and the resulting colonies were
stained with crystal violet.
doi:10.1371/journal.pone.0036510.g010
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doxorubicin or paclitaxel had an increased survival upon Gln
withdrawal than the unselected cells, as judged by the number of
colonies (Fig. S3). In such experiments, the chemoresistant
surviving cells were first allowed to recover in a drug-free complete
medium prior to subjecting them to glutamine withdrawal for 4–5
weeks. Previous studies with COX-2 overexpressing breast cancer
cells and chemotherapy resistant breast cancer cells suggest that
the high COX-2 expression in Gln-ind cells may account for their
resistance to chemotherapeutic drugs [26,30].
COX-2 overexpression in Gln-ind cells correlates with
celecoxib resistance
COX-2 expression in breast cancer cells may correlate with
response to a COX-2 inhibitor, e.g., celecoxib. But COX-2
overexpression may also be responsible for resistance to celecoxib
in a subpopulation of breast cancer cells [30,35,36]. We have
found that a small subpopulation of SUM149 cells can tolerate
10–20 mM celecoxib [30]. Celecoxib-resistant SUM149 cells
express a higher level of COX-2 than the parental cell line,
indicating that the resistance to celecoxib is driven by COX-2
overexpression [30]. In another studies involving mouse models of
breast cancer, a COX-2 inhibitor (celecoxib or SC-236) delayed/
inhibited tumor growth; however, resistance to COX-2 inhibitors
developed due to overexpression of COX-2 in tumors [35,36].
Initially we found that both parental cell line and Gln-ind cell line
contain a significant number of cells that readily survive exposure
to 10 mM celecoxib. To determine whether Gln-ind cells have a
high potential to drive resistance to celecoxib, we treated Gln-ind
cells and parental SUM149-Luc cell line (both in complete
medium with glutamine) with 50 mM celecoxib for 5 days. Then
we allowed the celecoxib-resistant cells to recover in the medium
without celecoxib. In this manner we found that Gln-ind cells, but
not parental cell line, contained cells capable of surviving in the
presence of 50 mM celecoxib for 5 days. Such celecoxib-resistant
Gln-ind cells produced colonies of cells that could be grown
indefinitely in culture (Fig. 12).
To further demonstrate the importance of COX-2 in the Gln-
ind phenotype, we first selected cells from the parental cell line
after treatment with 10 mM celecoxib for 7 days, allowed them to
recover in a drug-free medium for 3 days, and then subjected them
to Gln withdrawal. In this manner we found that celecoxib-
resistant SUM149 cells produced more Gln-ind colonies than the
parental cell line treated with the solvent DMSO alone (Fig. S4).
These results indicate that COX-2 overexpression has an important
role in the survival of Gln-ind cells in the absence of Gln.
Gln-ind cells are more tumorigenic and more metastatic
than the parental cell line
We determined the ability of Gln-ind cells to form tumors and
to metastasize in a nude mouse xenograft model. We injected 200
to 2 million luciferase-transfected cells into the thoracic fat pads of
nude mice in duplicate and monitored tumor growth and skin
metastasis by using whole-body luciferase imaging. Because of a
relatively high luciferase signal emanating from the primary tumor
in fat pad, which is in the vicinity of lungs, it is not feasible to
detect lung metastasis by luciferase imaging. Therefore, we chose
to analyze lung metastasis by performing a luciferase activity assay
in homogenates from lungs. We showed in a recent study that
when nude mice were injected into fat pad with 2 million
SUM149-Luc cells, all mice developed lung metastasis as detected
by luciferase activity [37]. This result is consistent with an earlier
study from another laboratory in which 1 million SUM149 cells
were injected and lung metastases were analyzed by examining
foci [29]. In another study performed with our SUM149-Luc cell
line, lung metastasis was detected with ex vivo luciferase imaging
(inject D-luciferin into mice, harvest lungs, and image), which
correlated with detection by hematoxylin and eosin staining of a
lung tissue section [38].
In the present study, mice injected with 2 million or 200,000
SUM149-Luc parental cells developed lung metastases. However,
lung metastases were detected in only one of the two mice injected
with 20, 000 SUM149-Luc cells (both mice developed primary
tumor). Lung metastasis was not detected in the one mouse
injected with 2,000 SUM149-Luc cells that developed primary
Figure 12. Celecoxib resistance in Gln-ind cells. One million cells
of parental SUM149-Luc cell line or Gln-ind cells were treated with
50 mM celecoxib and rare surviving cells were allowed to grow into
colonies. Then cells were dispersed by trypsinization and plated in
dishes in medium with glutamine (complete medium) or without
glutamine.
doi:10.1371/journal.pone.0036510.g012
Figure 11. Increased resistance to doxorubicin and paclitaxel
in Gln-ind cells. Parental SUM149-Luc cell line or Gln-ind cells were
treated with 200 nM doxorubicin (top) or 5 nM paclitaxel (bottom) for 7
days as described in Materials and Methods, and allowed to recover in a
drug-free medium for 2 weeks (doxorubicin-treated) or 1 week
(paclitaxel treated) before staining the colonies.
doi:10.1371/journal.pone.0036510.g011
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metastasis). In contrast, all the mice injected with Gln-ind cells,
including those injected with 200 cells, developed lung metastases.
Figure 13 includes luciferase images of 2 mice in the control group
and one mouse in the Gln-ind group, their tumor weights, and
luciferase activity in lungs; all the data shown in Figure 13 was
collected in parallel at the same time. Significantly, as the number
of injected cells was reduced, lung metastasis was not observed in
the mice injected with the parental cell line even though they had
good primary tumor growth (Fig. 13). We sacrificed all the
remaining mice in this experiment at day 153 after injecting the
cells. We found that one mouse injected with 200 parental
SUM149-Luc cells developed a very slow growing tumor,
detectable by luciferase imaging after 3 months and primary
tumor weighing 0.04 g at day 153. The other mouse injected with
200 parental SUM149 cells and one of the two mice injected with
2,000 parental SUM149 cells lacked tumor growth by day 153. All
mice injected with Gln-ind cells, including both mice injected with
only 200 cells, developed tumors that could be easily observed by
luciferase imaging as early as 62 days (Fig. 14). Relative tumor
burden in all remaining mice at an early time point, as detected by
luciferase imaging at day 34, is also shown (Fig. S5). To sum up, as
we decreased the number of cancer cells in xenografts, lung
metastasis and then primary tumor growth was impaired in mice
injected with the parental SUM149-Luc cells, but not in mice
injected with glutamine-independent cells. These observations,
particularly from the mice injected with 20,000 or less cells,
suggest that Gln-ind cells are more tumorigenic (more incidence
and faster appearance of primary tumor) and more metastatic
(more incidence of lung metastasis) than the parental cell line.
Inflammatory breast cancer is well known to metastasize to skin.
To compare Gln-ind cells with the parental SUM149-Luc cell line
for an ability to cause skin metastasis, we chose representative
luciferase images in the two groups such that the primary tumor
burden in the two groups was comparable (Fig. S6). Although we
imaged the mice on different days, we normalized the images for
comparison using a common minimum and maximum setting in
the Living Image program. In this manner, we found that Gln-ind
cells caused more skin metastasis than the parental cells, which is
observed as luciferase-positive spots scattered on the body (see
spots inside the red rectangles in Fig. S6). We confirmed metastasis
to skin by performing ex vivo luciferase imaging on dissected skin
from two mice at the end of the experiment. This data, showing
luciferase positive signal in the skin of a mouse each injected with
the parental SUM149-Luc and Gln-ind cells, is presented (Fig. S7).
These data along with the lung metastasis data presented above
Figure 13. Increased lung metastasis in nude mice injected
with Gln-ind cells. Luciferase images of mice injected into fat pad
with indicated cell type and cell number were collected at day 83. The
three mice were sacrificed on day 90, their primary tumors were
weighed, and luciferase activity was determined in their lungs. The data
indicate that lung metastasis was impaired in the mice injected with
20,000 or 2,000 SUM149-Luc cells. In contrast all mice injected with Gln-
ind cells, including those injected with 200 cells, developed lung
metastasis.
doi:10.1371/journal.pone.0036510.g013
Figure 14. Impairment of primary tumor growth in mice injected with parental SUM149-Luc cells, but not with Gln-ind cells, upon
reducing the number of injected cells. Cells (200 to 2 million) were injected into thoracic fat pads of 44-day-old nude mice (decreasing cell
number from left to right) in duplicate. The luciferase images collected at day 62 show that primary tumor growth in the mice injected with the
parental cell line was significantly reduced or absent upon reducing the number of injected cells below 2,000. In contrast, all mice injected with Gln-
ind cells developed tumors, including both mice injected with only 200 cells. Empty slots on the left correspond to the mice that needed to be
sacrificed because of high tumor burden.
doi:10.1371/journal.pone.0036510.g014
In Vitro Selection of Metastatic Cancer Cells
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36510indicate an overall more malignant nature of Gln-ind cells than
the parental cell line.
On a separate note, although we had not designed this study to
compare metastases to other organs, we analyzed metastases to
brain and liver in one mouse each injected with 200,000 SUM149-
Luc cells, and 20,000 Gln-ind cells. This data along with luciferase
images, tumor weight, and lung metastasis information for these
mice is shown (Fig. S8). We found both mice to be positive for
metastases in both brain and liver by luciferase activity assay on
tissue homogenates, indicating that the xenograft mouse model
recapitulates aggressive features of IBC.
Overexpression of cadherin11 and vimentin in Gln-ind cells
To determine a molecular basis of increased metastasis, we
analyzed cadherin11 level in Gln-ind cells. We predicted a high
cadherin11 expression from a gene expression profile in COX-2
overexpressing celecoxib-resistant SUM149-CER cell line (B
Singh and A Lucci, unpublished data). Cadherin11, also known
as mesenchymal cadherin, is expressed in cancer cells undergoing
epithelial to mesenchymal transition (EMT). Cadherin11 could be
important in cell motility, invasion, homotypic cell-cell interac-
tions, and in cancer cell interaction with stroma [39]. We found by
western blot analysis that cadherin11 level is significantly higher in
Gln-ind cells than parental SUM149 cells (Fig. 15). Others have
shown that EMT correlates with cancer stem cell phenotype [40].
We also analyzed intermediate filament protein vimentin, another
important marker of EMT, and found by western blotting and by
Coomassie blue staining that vimentin is overexpressed in Gln-ind
cells (Fig. 16). We also found that siRNA-mediated COX-2
knockdown in a transient transfection experiment did not affect
vimentin level (Fig. 16), as would be expected for a relatively stable
protein.
In a separate experiment, we found that, similar to our previous
study showing high pro-urokinase plasminogen activator (pro-
uPA) expression in COX-2 overexpressing breast cancer cell lines
[20], pro-uPA is overexpressed in Gln-ind cells (B Singh, AM
Cady, and A Lucci, unpublished data), providing a basis of
invasion into basement membrane. These results, along with the
results on cellular adaptability, provide a basis of increased
tumorigenicity and metastatic potential of Gln-ind cells.
Discussion
Genetic and epigenetic heterogeneity among cancer cells in a
tumor is a major impediment to personalized therapy. Current
approaches of personalized therapy, mostly designed to inhibit cell
proliferative function of a single protein, may not succeed unless
we target adaptability of cancer cells as well. Our study suggests
that it is feasible to select highly adaptable rare cancer cells by
depriving them of glutamine for an extended period. This
approach can be extended to other components in the culture
medium, such as glucose, other amino acids, oxygen, etc. Different
deprivations will likely select for common elements that are
important in adaptable metabolic state, as well as some nutrient-
specific elements required for survival and growth under these
conditions. Currently, therapeutic approaches are being designed
to inhibit cancer metabolism in the bulk of proliferating cancer
cells [41,42]. Investigation of highly adaptable metastatic cancer
cells that survive without specific nutrients may teach us about the
mechanisms of resistance to metabolism-based and cell prolifer-
ation-based therapies and help develop strategies to counter such
resistance.
The selection in a medium without glutamine or without
glucose would likely favor cells that are able to survive high
oxidative stress. Aggressive breast cancer cell lines are character-
ized by a high level of oxidative stress as indicated by low GSH
and low GSSG levels [43]. Since SUM149 is a very aggressive cell
line, it is likely to have a relatively high oxidative stress. Lack of
nutrients is likely to further increase stress, possibly killing most
cells. An alternative reason for the death of most (.99.99%) cells
upon glutamine withdrawal could be nutrient sensing response,
not directly involving stress response [14]. The rare cells that
survive do so either by an ability to tolerate more stress or by other
mechanisms for dealing with nutrient unavailability. Our results
indicate that Gln-ind cells have even lower levels of GSH and
GSSG than the parental cell line (Fig. S1). Our results also provide
evidence that oxidative stress in Gln-ind cells may be responsible
for COX-2 overexpression and NFkB activation (Figs. 7, S2).
There is evidence that stress influences epigenetic state by affecting
DNA methylation and histone modifications [44]. It is reasonable
that the epigenetic state created in this manner would also allow
Figure 15. Increased level of cadherin11 in Gln-ind cells. We
detected cadherinl1 level by western blotting in parental SUM149-Luc
cell line and Gln-ind cell line both growing in a medium with Gln, and
Gln-ind cells growing without Gln as indicated at the bottom.
doi:10.1371/journal.pone.0036510.g015
Figure 16. Detection of vimentin in Gln-ind cells. Left, We
transfected SUM149-Luc and Gln-ind cells with a COX-2 specific siRNA
or a negative control siRNA, allowed cells to grow for 3 days with or
without Gln as indicated at the bottom, and then subjected them to
western blotting to detect vimentin. Right, Lysates from parental
SUM149-Luc cell line and Gln-ind cells were analyzed by SDS-PAGE
followed by Coomassie blue staining. A prominent vimentin-size band,
which is present in Gln-ind cells and absent in parental cell line, is
indicated by an arrow. Left lane shows prestained molecular weight
markers. All samples were run on a single gel; however, we excised
some irrelevant lanes that were present between the lanes of interest.
doi:10.1371/journal.pone.0036510.g016
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able to tolerate extreme stresses including those imposed by
metabolic challenges are endowed with a unique epigenetic state.
One way to explain tumor heterogeneity and therapeutic
resistance is that a subpopulation of stem-like cancer cells governs
these properties. The idea that rare cancer cells resembling stem
cells or progenitor cells in the breast drive breast cancer has a
widespread support. In this study with an emphasis on clinical
translation, we approached the problem of cellular heterogeneity by
selecting for metabolically plastic aggressive cancer cells. We believe
that the cellular adaptability may be an important feature of
stemness. In this regard, a recent study found that glioma stem cells,
but not ‘‘differentiated’’ glioma cells, possess a flexible metabolic
state that allows them to use multiple metabolic pathways for
producing energy [45]. In the current and future studies, it will be
our high priority to determine whether we can eradicate Gln-ind
cells with therapies being developed to target cancer stem cells.
How does our method of enriching metastatic cancer cells
compare with other function-based in vitro selection methods? One
prominent method, which has been used in several studies with
cancer cell lines from different organ sites including breast, involves
selection of anchorage-independent cells in soft agar or hard agar.
The method selects for invasive cells that are metastatic in xenograft
mousemodels[46–50].Importantly,highlyanchorage-independent
cells selected in this manner are metastatic not only in immuno-
compromised nude mice, but also in immunocompetent syngeneic
mice [46,47]. Significantly, Gln-ind cells are more anchorage-
independent than parental cells (Fig. 10B). It will be useful to find
out in the future whether metastatic cancer cells selected on hard
agar are more metabolically adaptable as well. It will also be
important to learn whether Gln-ind cells are metastatic in
immunocompetent mice. This issue can be addressed by using the
Gln-ind cells we have selected from mouse breast cancer cell lines
4T1, 4T07, and 168FARN (Fig. 2). The advantages in our selection
as compared to growth in hard agar are that our selection is well
defined and easy to perform, and such selection is likely to occur in
the body. Ourmethod has the likelihoodof being applicable to most
tumor types and subtypes, and capable of selecting a large spectrum
of cellular heterogeneity. To conclude, both methods have unique
strengths that make them useful. Although the two selection
methods are different at the surface, both may be able to select
adaptable cells, one by virtue of metabolic plasticity, and the other
one by virtue of structural plasticity.
The question at this time is whether the in vitro assays will be
useful in discovering safe and effective therapies to prevent and
cure metastasis. Obviously it would be better to attack the problem
before micrometastases progress to clinical metastasis. Given a
high failure rate of new therapies in the clinic, it is most important
that we have superior preclinical models, and that candidate
therapies pass more rigorous tests of efficacy before they are tested
in patients. Then we will be in a better position to attack the
disease that has often ‘‘evolved’’ in the body for decades. We
believe superior in vitro testing will play a significant role in the
development of combination therapies that will be required to
combat aggressive cancers.
Materials and Methods
Ethics statement
The studies with nude mice were performed under an animal
protocol (ACUF Protocol # 12-10-11431 entitled ‘‘Metabolic
plasticity in breast cancer metastasis’’, Principal Investigator-
Anthony Lucci) approved by the University of Texas MD Anderson
Cancer Center Institutional Animal Care and Use Committee.
Cell lines and culture
MCF10A and MCF10A-COX2 (COX-2-transfected) cell lines
[25] were maintained in DMEM/F12 medium supplemented with
5% heat-inactivated horse serum (Invitrogen, Carlsbad, CA),
10 mg/ml of insulin, 20 ng/ml of epidermal growth factor,
0.1 mg/ml of cholera toxin, 0.5 mg/ml of hydrocortisone, 100
units/ml of penicillin, and 100 mg/ml of streptomycin. The MCF7,
MDA-MB-231, and MDA-MB-231-BSC60 cell lines were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS), 100 U/ml of penicillin, and 100 mg/ml of streptomycin.
MDA-MB-231-BSC60 is a metastatic variant of MDA-MB-231
isolated in our laboratory after two rounds of selection in female
nude mice by cardiac ventricle inoculation followed by cell culture
from bone metastases [21]. The SUM149 and SUM190 inflam-
matory breast cancer cell lines, originally obtained from Stephen
Ethier (Barbara Ann Karmanos Cancer Institute, Detroit, MI,
USA), were grown in Ham’s F-12 medium supplemented with 5%
FBS, 5 mg/ml of insulin, 1 mg/mL of hydrocortisone, 100 U/ml of
penicillin, and 100 mg/ml of streptomycin in a humidified 5% CO2
atmosphere. We have previously described SUM149-Luc, a
luciferase-transfected cell line [37], and SUM149-CER, a cele-
coxib-resistant COX-2 overexpressing cell line [30]. SUM149-FP is
another cell line recently developed in our laboratory by first
culturing from a SUM149 xenograft in a female nude mouse and
then culturing from a fat pad xenograft. 4T1, 4T07, and 168FARN
mouse breast cancer cell lines with different metastatic potential,
originally isolated in the laboratory of Fred Miller [51], were
obtained from Ralph Arlinghaus (MD Anderson Cancer Center)
and grown in DMEM/F-12 medium supplemented with 10% FBS.
Assay of glutamine dependence of cell lines
Initially, we surveyed breast cancer cell lines for their relative
dependence on glutamine (Gln) for growth. For this purpose, we
platedhalfa million cells in10-cmdishes.The next day, we removed
the medium, rinsed the dishes twice with phosphate-buffered saline,
and added new medium containing dialyzed FBS (Invitrogen) and
lacking Gln. We followed the cultures to determine the effects of
long-term deprivation of Gln. If a culture grew with little effect of
Gln deprivation, e.g., the MCF10A cell line, we passaged it at least 3
times in Gln-free medium to confirm that the culture can grow
without Gln. On the other hand, if Gln withdrawal in the initial dish
resulted in near-complete inhibition, e.g., in the highly aggressive
SUM149 cell line, we followed these dishes for 3–4 weeks to
determine if some variants would survive and produce colonies.
Selection and culture of Gln-ind variants
The main purpose of this study was to investigate rare Gln-ind
variants in aggressive breast cancer cell lines. We noticed in the
initial experiments that the cell lines that were cultured in Ham’s F-
12 medium yielded healthier colonies of Gln-ind cells, and the Gln-
ind cells proliferated well in this medium. Therefore, we utilized
both Ham’s F-12 medium and the culture medium in which a
particular cell line is usually cultured to select Gln-ind variants. In
this manner, we found that Ham’s F-12 medium is superior to other
media for selecting and culturing Gln-ind cells. To make the
selection highly robust, we waited for at least 3–4 weeks, until the
Gln-addicted cells were completely eliminated. When the colonies
grew to a size easily visible with the naked eye, we counted the
number of colonies and began passaging them for long-term
culture. Most Gln-ind variants selected in this manner could be
cultured long-term in Gln-free medium. However, Gln-ind variants
isolated from some cell lines required Gln for long-term culture.
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We performed COX-2 knockdown in the SUM149-CER cell line
[30] using COX-2-specific Silencer Select siRNA s11473 and a
Silencer Select negative control #1 siRNA (both from Applied
Biosystems, Foster City, CA), along with siPORT NeoFX transfec-
tion agent (Applied Biosystems), according to the manufacturer’s
instructions. We performed COX-2 knockdown in Gln-ind cells
similarly,exceptthatweusedculturemediumlackingGlnduringthe
transfection.
Western immunoblotting
We separated proteins by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and detected various
proteins by western blotting, as described previously [18] using
the ECL Advance western blot detection reagents (GE Healthcare
Biosciences, Piscataway, NJ). The following primary antibodies
were used for detection: anti-COX-2 monoclonal antibody
(Cayman Chemical, Ann Arbor, MI), anti-GLS (Abcam, Cam-
bridge, MA), anti-Myc, anti-LDH A, anti-hexokinase II, anti-
GAPDH, anti-cadherin11, and anti-vimentin antibodies (Cell
Signaling, Danvers, MA). The filters were stripped by incubating
the membrane in 0.5% Triton X-100 and were re-probed with a
monoclonal b-actin antibody (Sigma-Aldrich, St. Louis, MO) or
with Hsp90 antibody (Cell Signaling), which served as gel-loading
controls. We performed each western blot at least 3 times. We
quantified the protein bands on x-ray films by using the ImageJ
image processing program (National Institutes of Health).
Adaptability assays
To determine the adaptability of the Gln-ind cells, we
developed two assays: one for adaptability to face metabolic
challenges and the other one to face a lack of growth factors. To
determine adaptability of the metabolic state of Gln-ind cells, we
deprived them of glucose for 28 days and assessed whether a
higher number of cells survived compared with those surviving
glucose deprivation in the parental cell line. Cancer cells are highly
addicted to glucose, so the majority of them are expected to die in
the absence of glucose. The basis of the assay is that the survival of
rare cells under extreme glucose deficiency for an extended period
is likely to select for cells with a highly adaptable metabolic state.
We plated a half million cells on a 10-cm dish, switched them to
glucose-free medium (custom medium from (AthenaES, Balti-
more, MD) for 28 days, and then switched them back to complete
medium for 2 weeks until the surviving cells yielded colonies. We
stained the colonies with crystal violet and photographed them.
Factors present in serum regulate cell, which also involves
instructing a cell to proliferate. The rationale for our second assay
is that highly adaptable rare cancer cells that drive the disease must be
relatively less dependent on extr i n s i cf a c t o r sa sc o m p a r e dt ot h e
majority of cancer cells. In thisassay, we plated a halfmillion cellson a
10-cm dish and switched them to medium without serum on a
permanent basis, thus allowing sufficient time for the selection of rare,
highly adaptable cells that would survive and grow into colonies. We
stained the colonies with crystal violet and photographed them.
Soft-agar colony-forming assay
We plated 12,000 cells per well in a 6-well dish in 0.35% low-
melt agarose (Fisher Scientific, Pittsburgh, PA) in 1 mL of culture
medium containing glutamine and dialyzed FBS, which was
layered on the top of a 1-ml 0.5% agarose layer in the same
medium. We replenished the medium by adding 0.2 ml of
medium per well on a weekly basis. After 23 days, we stained
the colonies with crystal violet and photographed them.
Assays for resistance to chemotherapeutic drugs and
celecoxib
We plated one million cells per 10 cm dish in duplicate in
culture medium with glutamine. After 24 hours, we added
doxorubicin (0–400 nM) or paclitaxel (0–10 nM) dissolved in
DMSO. We continued drug treatment up to seven days while
monitoring drug response under microscope. Then we removed
the drug-containing medium, washed twice with PBS, and
incubated in the Gln-containing medium without drug for several
days until colonies visible to the naked eye appeared. Colonies
were stained with crystal violet and photographed. We determined
resistance to celecoxib in a similar manner by treating the cells
with 50 mM celecoxib for 5 days and then allowing the rare most
resistant cells to grow into colonies.
Xenograft experiments
We anesthetized 20 female athymic nude mice (Harlan,
Indianapolis, IN) 44 days old with isoflurane inhalation. We injected
Gln-ind or parental SUM149-Luc cells in amounts of 2 million, 0.2
million, 20,000, 2,000, or 200 cells each in duplicate mice
orthotopically into the upper left mammary fat pad. For each
injection, we suspended cancer cells in 0.05 ml of serum-free
medium and mixed them with an equal volume of Matrigel (Fisher
Scientific). Starting 14 days from the date the cancer cells were
injected, we used whole-body luciferase imaging (Xenogen IVIS
System 200; Caliper Life Sciences, Hopkinton, MA) to detect
primary tumors and skin metastases. Each mouse was given 1 mg
potassium salt of D-luciferin in 0.1 ml phosphate-buffered saline by
intraperitoneal injection and then anesthetized with isoflurane.
Starting 5 min after the D-luciferin injection, bioluminescent images
were collected for 1 min each in the ventral position. Generally, five
mice were imaged at a time. The levels of light emitted from the
bioluminescent tumor cells were detected by the IVIS camera
system, integrated, digitized, and displayed. We refer to tumor in the
fat pad as the primary tumor for clarity, although it was not possible
to distinguish primary tumors from local metastases. At the end of
the experiment, we euthanized the mice by CO2 inhalation and
resected and weighed the tumors. To quantify lung metastases, we
harvested lungs in 1 ml cell lysis buffer (25 mM Tris–phosphate,
pH 7.8, 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-
N,N,N9,N9-tetraacetic acid, 10% glycerol, 1% Triton X-100),
prepared the lysates by chopping the lungs into small pieces with a
scalpel followed by dounce homogenization, and assayed relative
luciferase activity with a kit (Promega) and a luminometer.
Supporting Information
Figure S1 A low level of glutathione in Gln-ind cells. We
prepared cell lysates from SUM149-Luc cell line (parental) and
Gln-ind cell line, both growing in a medium with Gln, and
measured reduced glutathione (GSH) and oxidized glutathione
(GSSG) with a kit from BioVision (Milpitas, CA). The GSH and
GSSG levels represent an average of 3 measurements normalized
to an equal protein basis.
(TIFF)
Figure S2 A reduction in COX-2 level upon treatment
with BAY-11-7082. We exposed parental SUM149-Luc and
Gln-ind cell lines both growing in a medium with glutamine (top
and middle panel), and Gln-ind cells growing without Gln (bottom
panel) to indicated concentrations of BAY-11-7082 or to DMSO
solvent alone for 24 hours before subjecting them to western
blotting using equal volumes of cell lysates.
(TIFF)
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selection of chemotherapeutic resistance. Parental
SUM149-Luc cells were treated with DMSO solvent alone or
with 200 nM doxorubicin for 3 days, allowed to recover in a drug-
free medium for 17 days, and then trypsinized and plated in
glutamine-free medium for 32 days before staining (top). Similarly,
parental SUM149-Luc cells were treated with DMSO solvent
alone or with 5 nM paclitaxel for 3 days, allowed to recover in a
drug-free medium for 28 days, and then trypsinized and plated in
glutamine-free medium for 34 days before staining (bottom).
(TIFF)
Figure S4 Increased glutamine independence pheno-
type in celecoxib-resistant cells. Parental SUM149-Luc cell
line was treated with DMSO solvent or with 10 mM celecoxib for
7 days. Celecoxib-resistant cells were allowed to recover in drug-
free medium for 3 days, and then trypsinized and plated in
glutamine-free medium at 0.5 million cells per 10 cm dish. Gln-
ind colonies were stained with crystal violet after 34 days.
(TIFF)
Figure S5 Gln-ind cells were more tumorigenic and
more metastatic in nude mice than the parental cell line.
Cells (200 to 2 million) were injected into thoracic fat pads of 44-
day-old nude mice (decreasing cell number from left to right) in
duplicate. Luciferase images collected at day 34 after injecting
cancer cells show higher tumor growth (compare luciferase signal
around fat pad) and skin metastasis (compare signal in dots away
from the injection site) in mice injected with Gln-ind cells (bottom)
than the parental SUM149 cell line (top). Empty slots on the left
correspond to the mice that needed to be sacrificed because of
high tumor burden.
(TIFF)
Figure S6 Increased skin metastasis in nude mice
injected with Gln-ind cells. Luciferase images of mice injected
with indicated cell type and cell number were collected at different
days. Images were chosen to have approximately similar luciferase
signal in primary tumors in mice injected with parental SUM149
(top) and Gln-ind cells (bottom). Skin metastases are indicated as
luciferase signals in red rectangles.
(TIFF)
Figure S7 Ex vivo imaging to confirm skin metastasis.
Skin away from primary tumor was dissected at day 25 from the
mice injected with 2 million parental SUM149-Luc cells (top) or
Gln-ind cells (bottom). The skin was placed in a petri dish
containing 0.5 mg D-luciferin in 10 ml PBS for 5 min, and
imaged with the Xenogen IVIS System 200.
(TIFF)
Figure S8 Detection of metastases to brain and liver.
Luciferase images of two mice injected with indicated cell type and
cell number were collected at the indicated days. The mouse
injected with the parental SUM149-Luc cells was sacrificed at day
67 (5 days after luciferase imaging), and the mouse injected with
Gln-ind cells was sacrificed at day 50 (2 days after luciferase
imaging). Tumors were weighed, and tissues were homogenized
(lungs and brain each in 1 ml, and liver in 1.5 ml) and luciferase
activity assayed as described for lung metastasis in Materials and
Methods. Total luciferase activity in tissues is shown as relative
luminescence units.
(TIFF)
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